| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 23 0 |
| Căutarea după subiecte similare conform CZU |
| 616.12-008.31 (32) |
| Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (1025) |
 SM ISO690:2012CAMERZAN, Iraida, COZONAC, Gheorghe, GARBUZ, Victor, GUŢU-BAHOV, Cornelia. The impact of pulse index continuous cardiac output technology on cost/efficiency in ICU. First experience. In: Moldovan Medical Journal, 2018, nr. 61(S_AIC), p. 26. ISSN 2537-6373. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Moldovan Medical Journal | ||||||
| Numărul 61(S_AIC) / 2018 / ISSN 2537-6373 /ISSNe 2537-6381 | ||||||
|
||||||
| CZU: 616.12-008.31 | ||||||
| Pag. 26-26 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Background: Currently, the correction guidelines of shocks of different genesis recommend PiCCO monitoring for infusion and vasopressor therapy. Purpose: assessing the impact of PiCCO technology on the cost/effectiveness principle in the ICU. Material and methods: The retrospective study was performed on a group of 125 critical patients divided into two groups, requiring vasopressors, inotropes or infusion therapy, hospitalized during the period 2017-2018 in ICU of the SCM “Sf. Treime”. The treatment was different depending on the reanimatological syndrome. Patients in group I (n = 60) were subjected to PiCCO-guided intensive therapy by measuring dynamic and volumetric parameters, ScvO2, SaO2, MAP, and group II (n = 65) - intensive therapy guided by measuring static parameters (PVC, ScvO2, MAP), with an insignificant difference in age and sex. Results: According to the study data, patients in group I received a higher APACHE II at hospitalization in ICU (lot I (APACHE 26, ISS 14) versus lot II (APACHE 24 p, ISS score 13), and at the end of the treatment – reduction of the hospitalization time in ICU (lot I (5.4 days) versus lot II (7.8 days) but with insignificant influence on the death rate. At the same time, it was noted a reduction in lethality in patients with ketoacidosis (lot I (14.28%) versus lot II (27.27%) in patients with IRA (lot I (0%) versus lot II (16.66%). Conclusions: Guided intensive therapy with PiCCO technology showed a 2.4 days/bed reduction, which implies lower costs ICU, but with an insignificant impact on lethality rates, especially in cardiogenic shock, septic shock, ARDS (Phase III). At the same time, there was a reduction of lethality in cases of ketoacidosis and IRA. |
||||||
| Cuvinte-cheie PiCCO technique, cost / efficiency, lethality |
||||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Camerzan, I.</dc:creator> <dc:creator>Cozonac, G.</dc:creator> <dc:creator>Garbuz, V.</dc:creator> <dc:creator>Guţu-Bahov, C.</dc:creator> <dc:date>2018-09-30</dc:date> <dc:description xml:lang='en'><p>Background: Currently, the correction guidelines of shocks of different genesis recommend PiCCO monitoring for infusion and vasopressor therapy. Purpose: assessing the impact of PiCCO technology on the cost/effectiveness principle in the ICU. Material and methods: The retrospective study was performed on a group of 125 critical patients divided into two groups, requiring vasopressors, inotropes or infusion therapy, hospitalized during the period 2017-2018 in ICU of the SCM “Sf. Treime”. The treatment was different depending on the reanimatological syndrome. Patients in group I (n = 60) were subjected to PiCCO-guided intensive therapy by measuring dynamic and volumetric parameters, ScvO2, SaO2, MAP, and group II (n = 65) - intensive therapy guided by measuring static parameters (PVC, ScvO2, MAP), with an insignificant difference in age and sex. Results: According to the study data, patients in group I received a higher APACHE II at hospitalization in ICU (lot I (APACHE 26, ISS 14) versus lot II (APACHE 24 p, ISS score 13), and at the end of the treatment – reduction of the hospitalization time in ICU (lot I (5.4 days) versus lot II (7.8 days) but with insignificant influence on the death rate. At the same time, it was noted a reduction in lethality in patients with ketoacidosis (lot I (14.28%) versus lot II (27.27%) in patients with IRA (lot I (0%) versus lot II (16.66%). Conclusions: Guided intensive therapy with PiCCO technology showed a 2.4 days/bed reduction, which implies lower costs ICU, but with an insignificant impact on lethality rates, especially in cardiogenic shock, septic shock, ARDS (Phase III). At the same time, there was a reduction of lethality in cases of ketoacidosis and IRA.</p></dc:description> <dc:source>Moldovan Medical Journal S_AIC (61) 26-26</dc:source> <dc:subject>PiCCO technique</dc:subject> <dc:subject>cost / efficiency</dc:subject> <dc:subject>lethality</dc:subject> <dc:title>The impact of pulse index continuous cardiac output technology on cost/efficiency in ICU. First experience</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
